LVTX - LAVA Therapeutics N.V. Price Target Chart

LAVA Therapeutics N.V. (LVTX) develops unique oncology drugs based on gamma-delta T-cells, protecting its research with patents for bispecific antibodies. This daily price chart confirms the market valuation of the asset, where the current figure is 1.36. The company's results depend on science rather than economics, although access to capital remains critical. The preclinical status of projects and reliance on partner payments hinder scaling amid rising costs.

LVTX - Lava Tx Consensus Target over the range 07/04/2022 - 12/06/2025

Metric breakdowns and analytics for Lava Tx (LVTX)

- current price and projected stock value:

Price Chart Lava Tx|LVTX - Consensus Target

- market capitalization statistics:

Market Value LAVA Therapeutics N.V.|LVTX - Real Price to Acquire Entire Company

- issuer book value statistics:

Book Price of a Share LAVA Therapeutics|LVTX - Company Net Assets|Capitalization to Book Value Ratio lavatherapeutics.com|LVTX - Aggregate Company Assets

- business debt structure and liquidity details:

- earnings and market ratios statistics:

LVTX - Company Net Income|Expected Net Profit LAVA Therapeutics N.V.|LVTX - P/E Multiple|Forward Price to Earnings Multiple Lava Tx|LVTX - Price/Earnings to Growth Multiple|Company Value to EBITDA LAVA Therapeutics N.V.|LVTX - Operating profit before deduction of amortization|Earnings per share for the trailing year LAVA Therapeutics|LVTX - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months lavatherapeutics.com|LVTX - Earnings per share growth in current year|Expected earnings per share growth for next year LAVA Therapeutics N.V.

- sales revenue and business income indicators:

LVTX - Company Revenue|Company Future Sales Volume Lava Tx|LVTX - Market Cap to Revenue|Forward P/S Multiple LAVA Therapeutics

General company analysis:LVTX (LAVA Therapeutics N.V.)

Mass-produced product of LAVA Therapeutics NV

Protected by international humanitarian immunity, the LAVA Therapeutics N.V. (LVTX) biotech sector minimizes geopolitical risks by focusing on the development of immuno-oncology drugs within the secure frameworks of the EU and US. Analysts' calculated price targets for the stock filter out market noise, revealing a gap between quotes and actual cash flows, which allows investors to objectively assess the fundamental imbalance and the asset's true value.

Competitors of LAVA Therapeutics N.V.